Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ-099
- Development stage
- Preclinical
- Lead developer
- Chengdu Huajian Science
01
Overview
HJ-099: sourced facts only. name: "Here, we report a novel, orally bioavailable pan-KRAS (ON) inhibitor HJ-099, designed to treat various KRAS mutation-driven tumors." [DOI:10.1158/1538-7445.am2025-4386]; target: "Here, we report a novel, orally bioavailable pan-KRAS (ON) inhibitor HJ-099, designed to treat various KRAS mutation-driven tumors." [DOI:10.1158/1538-7445.am2025-4386]; developer: "Chengdu Huajian Science Co., Ltd., Chengdu, China." [DOI:10.1158/1538-7445.am2025-4386]; stage: "In multiple KRAS mutated xenograft mouse models, HJ-099 showed significant inhibition on tumor growth." [DOI:10.1158/1538-7445.am2025-4386]
02
Targets
Beyond the preview
Go deeper on HJ-099.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ-099.